Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Total Revenue
--
1,313,646
1,116,854
889,895
Cost of Revenue
--
241,786
209,620
152,008
Gross Profit
--
1,071,860
907,234
737,887
Operating Expenses
Research Development
--
610,753
661,905
634,806
Selling General and Administrative
--
554,336
476,593
402,271
Non Recurring
--
--
--
--
Others
--
46,471
(26,953)
(17,690)
Total Operating Expenses
--
1,211,560
1,111,545
1,019,387
Operating Income or Loss
--
(139,700)
(204,311)
(281,500)
Income from Continuing Operations
Total Other Income/Expenses Net
--
131,679
(594,727)
160,682
Earnings Before Interest And Taxes
--
3,107
(794,918)
(119,774)
Interest Expense
--
38,982
36,132
34,950
Income Before Tax
--
(35,875)
(831,050)
(154,724)
Income Tax Expense
--
81,167
(200,840)
17,075
Minority Interest
--
--
--
--
Net Income From Continuing Ops
--
(117,042)
(630,210)
(171,799)
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
--
0
0
0
Net Income
--
(117,042)
(630,210)
(171,799)
Preferred Stock And Other Adjustments
--
--
--
--
Net Income Applicable To Common Shares
--
(117,042)
(630,210)
(171,799)

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq®
Brineura®
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information